頭頸部鱗狀細胞癌市場－全球產業規模、佔有率、趨勢、機會、預測：按類型、治療方法、給藥途徑、最終用戶、地區和競爭格局分類，2021-2031年

全球頭頸部鱗狀細胞癌 (HNSCC) 市場預計將從 2025 年的 24.9 億美元大幅成長至 2031 年的 40.9 億美元，複合年成長率為 8.62%。

頭頸部鱗狀細胞癌（HNSCC）是指起源於口腔、喉嚨和喉部黏膜的惡性腫瘤。此市場成長的主要促進因素是人類乳突病毒（HPV）感染的顯著增加，以及吸菸和過量飲酒等風險因素的持續存在。此外，全球人口老化導致患者數量增加，對先進治療方法的需求也日益成長。例如，美國癌症協會估計，到2025年，美國將新增約59,660例口腔癌和咽癌病例。

然而，儘管存在這些強勁的成長動力，市場仍面臨許多挑戰，尤其是創新免疫療法和標靶治療的高成本。這些經濟障礙會顯著限制患者獲得有效治療的機會，尤其是在醫療資源有限的發展中地區。此外，傳統放射線治療的嚴重副作用常常導致患者難以堅持治療，並降低其生活品質。這些經濟負擔和臨床管理的挑戰共同構成了該領域整體擴張的主要障礙。

市場促進因素

市場擴張的主要促進因素是全球頭頸部鱗狀細胞癌 (HNSCC) 發病率的上升，而這源於吸煙、飲酒和人類乳突病毒 (HPV) 感染等主要危險因素的持續流行。日益加重的疾病負擔使得已開發經濟體和新興經濟體都迫切需要提高診斷準確性並擴大治療覆蓋範圍。隨著患者數量的增加，醫療系統被迫將更多資源投入腫瘤科服務，這反過來又直接擴大了篩檢和治療方法市場。美國國立衛生研究院 (NIH) 於 2025 年 9 月發布的《全球頭頸癌負擔》報告強調了這一情況的嚴峻性，指出 2022 年全球約有 947,211 例新發頭頸癌病例，表明有大量人群需要干預。

第二個關鍵驅動力是免疫療法和分子標靶療法的快速發展。這些療法透過引入高效生物製藥，從根本上改變了臨床療效，並提升了市場價值。製藥公司正大力投資於新型查核點抑制劑和聯合治療，這些療法與傳統的放射線治療相比，能夠提供更高的存活率。這些創新得到了後期臨床試驗突破性發現的支持，這些發現正在建立新的治療標準。例如，美國臨床腫瘤學會 (ASCO) 於 2025 年 6 月發表的 NIVOPOSTOP 試驗表明，在局部進行性鱗狀細胞癌患者的放射線治療中加入納Nivolumab單抗，可使疾病復發風險降低 24%。 Fierce Pharma 於 2025 年 4 月報告稱，默克公司的 Keytruda 在 KEYNOTE-689 試驗中，與標準治療相比，術前和術後使用Pembrolizumab可使復發或死亡風險降低 27%，進一步印證了這一競爭性進展。

市場挑戰

全球頭頸部鱗狀細胞癌市場成長的主要障礙是新型免疫療法和標靶治療的高昂費用。儘管這些先進治療方法已證實具有臨床療效，但其過高的價格給患者和醫療系統都帶來了沉重的經濟負擔。在醫療預算有限且往往缺乏足夠的報銷機制來涵蓋昂貴癌症治療費用的開發中國家，這種經濟負擔尤其嚴重。因此，相當一部分合格的患者無法獲得最佳治療，從而縮小了這些創新藥物的潛在市場規模。

這種經濟障礙會產生連鎖反應，阻礙市場進一步擴張。通常，高昂的自付費用迫使患者延遲或放棄重要的醫療程序，導致治療順從性降低和藥物使用量減少。美國癌症協會癌症行動網路2025年的一項調查凸顯了這一點，調查發現，31%的成年人推遲尋求推薦的癌症醫療保健服務超過一年，其中超過一半的人表示自付費用是主要原因。這種經濟壓力不僅限制了先進藥物的引進，也使臨床管理複雜化，最終阻礙了該行業的收入成長潛力。

市場趨勢

人工智慧驅動的放射組學正在革新頭頸部腫瘤的臨床管理，它彌補了傳統影像診斷在識別隱匿性轉移方面的不足，從而提高了診斷和預後的準確性。目前，先進的機器學習演算法已被應用於分析從PET和電腦斷層掃描中獲得的複雜定量數據，實現了對淋巴結轉移的精準非侵入性檢測。這項技術進步使得制定更個人化的手術和放射治療方案成為可能，能夠有效靶向高風險區域，同時減少不必要的干涉。 2025年2月發表於《神經放射學》（Neuroradiology）雜誌的Meta分析報告稱，深度學習模型在使用PET/CT圖像診斷淋巴結轉移時，曲線下面積（AUC）達到了92%。

同時，治療性癌症疫苗和溶瘤病毒療法的興起，標誌著癌症治療正朝著主動免疫療法方向發生重大轉變，旨在預防高風險患者術後疾病復發。與被動查核點抑制劑不同，這些創新治療方法利用患者特異性新抗原和病毒載體激活免疫系統，對抗殘留癌細胞，從而提供毒性更低、療效更佳的根治性治療方案。這一趨勢在輔助性治療領域尤其重要，因為維持緩解仍然是該領域關鍵且尚未解決的臨床挑戰。根據Transgene公司2024年11月發布的新聞稿《Transgene和NEC公佈最新數據》，TG4050新抗原疫苗展現出顯著療效，所有16名接受治療的患者在中位追蹤24.1個月後均未出現疾病復發。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：頭頸部鱗狀細胞癌的全球市場展望

• 市場規模及預測
  • 按金額
• 市佔率及預測
  • 依類型（唾液腺、口腔/口咽、鼻腔/鼻竇、鼻咽、喉、下嚥）
  • 依治療方法（放射線治療、化療、免疫療法）
  • 給藥途徑（口服、靜脈注射、其他）
  • 依最終使用者（醫院/診所、門診中心、其他）分類
  • 按地區
  • 按公司（2025 年）
• 市場地圖

第6章：北美頭頸部鱗狀細胞癌市場展望

• 市場規模及預測
• 市佔率及預測
• 北美洲：國別分析
  • 美國
  • 加拿大
  • 墨西哥

第7章：歐洲頭頸部鱗狀細胞癌市場展望

• 市場規模及預測
• 市佔率及預測
• 歐洲：國別分析
  • 德國
  • 法國
  • 英國
  • 義大利
  • 西班牙

第8章：亞太地區頭頸部鱗狀細胞癌市場展望

• 市場規模及預測
• 市佔率及預測
• 亞太地區：國別分析
  • 中國
  • 印度
  • 日本
  • 韓國
  • 澳洲

第9章：中東和非洲頭頸部鱗狀細胞癌市場展望

• 市場規模及預測
• 市佔率及預測
• 中東與非洲：國別分析
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 南非

第10章：南美洲頭頸部鱗狀細胞癌市場展望

• 市場規模及預測
• 市佔率及預測
• 南美洲：國別分析
  • 巴西
  • 哥倫比亞
  • 阿根廷

第11章 市場動態

• 促進因素
• 任務

第12章 市場趨勢與發展

• 併購
• 產品發布
• 近期趨勢

第13章 全球頭頸部鱗狀細胞癌市場：SWOT分析

第14章：波特五力分析

• 產業競爭
• 新進入者的潛力
• 供應商的議價能力
• 顧客權力
• 替代品的威脅

第15章 競爭格局

• Bristol-Myers Squibb Company
• Merck & Co., Inc.
• F. Hoffmann-La Roche Ltd
• Pfizer Inc.
• AstraZeneca PLC
• Eli Lilly and Company
• Novartis AG
• Sanofi SA
• Bayer AG
• GlaxoSmithKline plc

第16章 策略建議

第17章：關於研究公司及免責聲明

The global market for Head and Neck Squamous Cell Carcinoma (HNSCC) is projected to expand significantly, rising from USD 2.49 Billion in 2025 to USD 4.09 Billion by 2031, demonstrating an 8.62% CAGR. HNSCC is defined as a malignant growth originating from the mucosal lining of the oral cavity, pharynx, and larynx. This market growth is primarily propelled by the ongoing presence of risk factors like tobacco use and excessive alcohol intake, coupled with a notable rise in Human Papillomavirus infections. Moreover, the worldwide aging population contributes to an increasing patient pool, demanding sophisticated therapeutic approaches. For instance, the American Cancer Society estimates approximately 59,660 new cases of oral cavity and pharynx cancer will be diagnosed in the U.S. in 2025.

However, despite these strong growth impetuses, the market encounters considerable obstacles, particularly the elevated costs of innovative immunotherapies and targeted drugs. Such financial impediments can significantly restrict patient access to effective treatments, especially in developing regions with limited healthcare resources. Additionally, the severe toxic effects linked with conventional chemoradiation regimens frequently complicate patient adherence and diminish their quality of life. This confluence of economic strains and clinical management challenges poses a major hurdle that could hinder the sector's overall expansion.

Market Driver

The primary force propelling market expansion is the increasing global incidence of Head and Neck Squamous Cell Carcinoma (HNSCC), driven by the ongoing prevalence of key risk factors like tobacco use, alcohol consumption, and Human Papillomavirus (HPV) infections. This growing disease burden necessitates an urgent need for enhanced diagnostic accuracy and broader therapeutic accessibility in both developed and emerging nations. With the rising number of patients, healthcare systems are compelled to dedicate more resources to oncology services, thereby directly enlarging the market for screening and treatment options. The National Institutes of Health's September 2025 'Global burden of head and neck cancer' report highlights this significant scale, noting that approximately 947,211 new cases of head and neck cancer were diagnosed worldwide in 2022, signifying a vast population requiring intervention.

A second significant driver is the swift progress in immunotherapy and targeted therapeutics, which are fundamentally transforming clinical results and increasing market valuation through the introduction of highly effective biological treatments. Pharmaceutical firms are heavily investing in new checkpoint inhibitors and combination therapies that offer superior survival rates compared to conventional chemoradiation. These innovations are substantiated by breakthrough findings from late-stage trials that are setting new benchmarks for care. For example, the American Society of Clinical Oncology's June 2025 'NIVOPOSTOP' trial revealed that adding nivolumab to chemoradiotherapy decreased disease recurrence risk by 24% in patients with locally advanced squamous cell carcinoma. Further underscoring this competitive advancement, Fierce Pharma reported in April 2025 that Merck's Keytruda, in the KEYNOTE-689 trial, reduced the risk of recurrence or death by 27% with perioperative pembrolizumab compared to standard treatment.

Market Challenge

A significant impediment to the growth of the Global Head and Neck Squamous Cell Carcinoma market is the elevated cost associated with novel immunotherapies and targeted drugs. Although these advanced treatment options demonstrate clinical effectiveness, their excessively high prices result in substantial financial strain for both patients and healthcare systems. This economic burden is particularly severe in developing nations that operate with restricted healthcare budgets, often lacking adequate reimbursement structures to cover costly oncological therapies. As a direct consequence, a considerable portion of the eligible patient demographic is unable to access optimal care, thereby diminishing the potential market size for these pharmaceutical innovations.

This financial obstacle generates a cascading effect that hinders wider market expansion. Frequently, high out-of-pocket expenses compel patients to postpone or decline crucial medical interventions, leading to decreased treatment adherence and reduced utilization of medications. A 2025 survey by the American Cancer Society Cancer Action Network highlighted this, indicating that 31% of adults were over a year behind on recommended cancer healthcare services, with more than half attributing this delay primarily to out-of-pocket costs. Such economic pressures not only restrict the adoption of sophisticated drugs but also complicate clinical management, ultimately impeding the sector's potential for revenue growth.

Market Trends

The integration of AI-driven radiomics is revolutionizing the clinical management of head and neck cancers by addressing the deficiencies of conventional imaging in identifying hidden metastases, thereby offering enhanced precision in diagnosis and prognosis. Sophisticated machine learning algorithms are now being applied to analyze intricate quantitative data from PET and CT scans, facilitating the accurate, non-invasive detection of lymph node involvement. This technological advancement allows for more tailored surgical and radiotherapeutic treatment plans, reducing unnecessary interventions while effectively targeting high-risk regions. A meta-analysis published in Neuroradiology in February 2025, titled 'Diagnostic accuracy of radiomics and artificial intelligence models,' reported that deep learning models achieved a pooled Area Under the Curve (AUC) of 92% for diagnosing lymph node metastasis via PET/CT imaging.

Concurrently, the rise of therapeutic cancer vaccines and oncolytic viral therapies signifies a crucial shift towards active immunization methods aimed at preventing disease recurrence in high-risk patients following surgery. In contrast to passive checkpoint inhibitors, these innovative treatments employ patient-specific neoantigens or viral vectors to prime the immune system to combat remaining tumor cells, potentially offering a curative option with a more favorable toxicity profile. This trend holds particular significance in the adjuvant setting, where maintaining remission is a vital unmet clinical requirement. As reported by Transgene in November 2024, in their 'Transgene and NEC Present New Data' press release, the TG4050 neoantigen vaccine demonstrated remarkable effectiveness, with all 16 treated patients remaining disease-free after a median follow-up period of 24.1 months.

Key Market Players

• Bristol-Myers Squibb Company
• Merck & Co., Inc.
• F. Hoffmann-La Roche Ltd
• Pfizer Inc.
• AstraZeneca PLC
• Eli Lilly and Company
• Novartis AG
• Sanofi S.A.
• Bayer AG
• GlaxoSmithKline plc

Report Scope

In this report, the Global Head and Neck Squamous Cell Carcinoma Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Head and Neck Squamous Cell Carcinoma Market, By Type

• Salivary Gland
• Oral and Oropharyngeal
• Nasal Cavity & Paranasal Sinuses
• Nasopharyngeal
• Laryngeal
• Hypo Pharyngeal

Head and Neck Squamous Cell Carcinoma Market, By Treatment

• Radiation
• Chemotherapy
• Immunotherapy

Head and Neck Squamous Cell Carcinoma Market, By Route of Administration

• Oral
• Intravenous
• Others

Head and Neck Squamous Cell Carcinoma Market, By End-user

• Hospitals & Clinics
• Ambulatory Care Centers
• Others

Head and Neck Squamous Cell Carcinoma Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Head and Neck Squamous Cell Carcinoma Market.

Available Customizations:

Global Head and Neck Squamous Cell Carcinoma Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Head and Neck Squamous Cell Carcinoma Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Type (Salivary Gland, Oral and Oropharyngeal, Nasal Cavity & Paranasal Sinuses, Nasopharyngeal, Laryngeal, Hypo Pharyngeal)
  • 5.2.2. By Treatment (Radiation, Chemotherapy, Immunotherapy)
  • 5.2.3. By Route of Administration (Oral, Intravenous, Others)
  • 5.2.4. By End-user (Hospitals & Clinics, Ambulatory Care Centers, Others)
  • 5.2.5. By Region
  • 5.2.6. By Company (2025)
• 5.3. Market Map

6. North America Head and Neck Squamous Cell Carcinoma Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Type
  • 6.2.2. By Treatment
  • 6.2.3. By Route of Administration
  • 6.2.4. By End-user
  • 6.2.5. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Head and Neck Squamous Cell Carcinoma Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Type
      • 6.3.1.2.2. By Treatment
      • 6.3.1.2.3. By Route of Administration
      • 6.3.1.2.4. By End-user
  • 6.3.2. Canada Head and Neck Squamous Cell Carcinoma Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Type
      • 6.3.2.2.2. By Treatment
      • 6.3.2.2.3. By Route of Administration
      • 6.3.2.2.4. By End-user
  • 6.3.3. Mexico Head and Neck Squamous Cell Carcinoma Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Type
      • 6.3.3.2.2. By Treatment
      • 6.3.3.2.3. By Route of Administration
      • 6.3.3.2.4. By End-user

7. Europe Head and Neck Squamous Cell Carcinoma Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Type
  • 7.2.2. By Treatment
  • 7.2.3. By Route of Administration
  • 7.2.4. By End-user
  • 7.2.5. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Head and Neck Squamous Cell Carcinoma Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Type
      • 7.3.1.2.2. By Treatment
      • 7.3.1.2.3. By Route of Administration
      • 7.3.1.2.4. By End-user
  • 7.3.2. France Head and Neck Squamous Cell Carcinoma Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Type
      • 7.3.2.2.2. By Treatment
      • 7.3.2.2.3. By Route of Administration
      • 7.3.2.2.4. By End-user
  • 7.3.3. United Kingdom Head and Neck Squamous Cell Carcinoma Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Type
      • 7.3.3.2.2. By Treatment
      • 7.3.3.2.3. By Route of Administration
      • 7.3.3.2.4. By End-user
  • 7.3.4. Italy Head and Neck Squamous Cell Carcinoma Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Type
      • 7.3.4.2.2. By Treatment
      • 7.3.4.2.3. By Route of Administration
      • 7.3.4.2.4. By End-user
  • 7.3.5. Spain Head and Neck Squamous Cell Carcinoma Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Type
      • 7.3.5.2.2. By Treatment
      • 7.3.5.2.3. By Route of Administration
      • 7.3.5.2.4. By End-user

8. Asia Pacific Head and Neck Squamous Cell Carcinoma Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Type
  • 8.2.2. By Treatment
  • 8.2.3. By Route of Administration
  • 8.2.4. By End-user
  • 8.2.5. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Head and Neck Squamous Cell Carcinoma Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Type
      • 8.3.1.2.2. By Treatment
      • 8.3.1.2.3. By Route of Administration
      • 8.3.1.2.4. By End-user
  • 8.3.2. India Head and Neck Squamous Cell Carcinoma Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Type
      • 8.3.2.2.2. By Treatment
      • 8.3.2.2.3. By Route of Administration
      • 8.3.2.2.4. By End-user
  • 8.3.3. Japan Head and Neck Squamous Cell Carcinoma Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Type
      • 8.3.3.2.2. By Treatment
      • 8.3.3.2.3. By Route of Administration
      • 8.3.3.2.4. By End-user
  • 8.3.4. South Korea Head and Neck Squamous Cell Carcinoma Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Type
      • 8.3.4.2.2. By Treatment
      • 8.3.4.2.3. By Route of Administration
      • 8.3.4.2.4. By End-user
  • 8.3.5. Australia Head and Neck Squamous Cell Carcinoma Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Type
      • 8.3.5.2.2. By Treatment
      • 8.3.5.2.3. By Route of Administration
      • 8.3.5.2.4. By End-user

9. Middle East & Africa Head and Neck Squamous Cell Carcinoma Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Type
  • 9.2.2. By Treatment
  • 9.2.3. By Route of Administration
  • 9.2.4. By End-user
  • 9.2.5. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Head and Neck Squamous Cell Carcinoma Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Type
      • 9.3.1.2.2. By Treatment
      • 9.3.1.2.3. By Route of Administration
      • 9.3.1.2.4. By End-user
  • 9.3.2. UAE Head and Neck Squamous Cell Carcinoma Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Type
      • 9.3.2.2.2. By Treatment
      • 9.3.2.2.3. By Route of Administration
      • 9.3.2.2.4. By End-user
  • 9.3.3. South Africa Head and Neck Squamous Cell Carcinoma Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Type
      • 9.3.3.2.2. By Treatment
      • 9.3.3.2.3. By Route of Administration
      • 9.3.3.2.4. By End-user

10. South America Head and Neck Squamous Cell Carcinoma Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Type
  • 10.2.2. By Treatment
  • 10.2.3. By Route of Administration
  • 10.2.4. By End-user
  • 10.2.5. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Head and Neck Squamous Cell Carcinoma Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Type
      • 10.3.1.2.2. By Treatment
      • 10.3.1.2.3. By Route of Administration
      • 10.3.1.2.4. By End-user
  • 10.3.2. Colombia Head and Neck Squamous Cell Carcinoma Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Type
      • 10.3.2.2.2. By Treatment
      • 10.3.2.2.3. By Route of Administration
      • 10.3.2.2.4. By End-user
  • 10.3.3. Argentina Head and Neck Squamous Cell Carcinoma Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Type
      • 10.3.3.2.2. By Treatment
      • 10.3.3.2.3. By Route of Administration
      • 10.3.3.2.4. By End-user

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Head and Neck Squamous Cell Carcinoma Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Bristol-Myers Squibb Company
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Merck & Co., Inc.
• 15.3. F. Hoffmann-La Roche Ltd
• 15.4. Pfizer Inc.
• 15.5. AstraZeneca PLC
• 15.6. Eli Lilly and Company
• 15.7. Novartis AG
• 15.8. Sanofi S.A.
• 15.9. Bayer AG
• 15.10. GlaxoSmithKline plc

16. Strategic Recommendations

17. About Us & Disclaimer